Optimizing Outcomes Using Suboxone for Opiate Dependence - Full Text View

Sponsored by:	University of California, Los Angeles
Information provided by:	University of California, Los Angeles
ClinicalTrials.gov Identifier:	NCT00591617

Purpose

Building on a platform of pharmacological treatment with Suboxone (buprenorphine and naloxone), participants are randomly assigned to one of four psychosocial treatment conditions.

Condition	Intervention
Opioid Dependence	Other: Psychosocial treatment plus Suboxone pharmacotherapy

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title:	Optimizing Outcomes Using Suboxone for Opiate Dependence

Resource links provided by NLM:

MedlinePlus related topics: Urine and Urination

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:

Comparison the effectiveness of four psychosocial treatment conditions as measured by self-reported abstinence from opioids verified by urine toxicology tests [ Time Frame: Over course of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Comparison across treatment conditions for reducing the severity of opioid-related problems [ Time Frame: Across the study duration ] [ Designated as safety issue: No ]
Comparison across treatment conditions for reducing the proportion of use-days of other substances of abuse (alcohol, marijuana, amphetamines, methamphetamines, benzodiazepines and barbiturates) as determined by self-report and urine test results. [ Time Frame: Across the study duration ] [ Designated as safety issue: No ]
Comparison across treatment conditions in reducing psychiatric and mood disturbance as measured with the BDI and SF-36. [ Time Frame: Across the study duration ] [ Designated as safety issue: No ]

Estimated Enrollment:	240
Study Start Date:	September 2006
Estimated Study Completion Date:	May 2011
Estimated Primary Completion Date:	January 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: MM: Active Comparator Medical Management: group receives medical management from study physician and Suboxone pharmacotherapy	Other: Psychosocial treatment plus Suboxone pharmacotherapy Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
2: CBT: Active Comparator Cognitive Behavioral Therapy (CBT) group receives CBT, medical management and Suboxone pharmacotherapy	Other: Psychosocial treatment plus Suboxone pharmacotherapy Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
3: CM: Active Comparator Contingency Management (CM) group receives CM, medical management, and Suboxone pharmacotherapy	Other: Psychosocial treatment plus Suboxone pharmacotherapy Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
4: CBT + CM: Active Comparator Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) group receives CBT, CM, medical management, and Suboxone pharmacotherapy	Other: Psychosocial treatment plus Suboxone pharmacotherapy Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)

Detailed Description:

The approval of buprenorphine (combined with naloxone as Suboxone®) by the FDA enables physicians in the United States to provide pharmacotherapy treatment to opioid-dependent patients in private medical settings. Buprenorphine's wide acceptance and implementation by physicians has been slower than expected, however, and this may be due in part to the nature and necessity of providing comprehensive treatment for opioid-dependent patients.

Lessons learned from methadone maintenance make it clear that simply providing opioid substitution does not address the behavioral components of dependence. While there is no lack of behavioral treatment facilities for substance abuse in the United States, what is lacking is an integrative approach to the treatment of opioid dependence using pharmacotherapy in conjunction with proven behavioral treatment strategies. Following a two-week stabilization and baseline period, this project will randomize 240 participants into 4 behavioral treatment groups featuring cognitive behavioral therapy and contingency management therapy. A universal, manual-guided psychosocial standard of care for buprenorphine pharmacological treatment allows for ethical inclusion of a "no-CBT or CM therapy" condition and closely resembles the current standard of psychosocial care delivered with opioid treatment using Suboxone®. Behavioral therapies will be delivered for 16 weeks (to study week 18) in conjunction with continued care with Suboxone®. An additional 16 weeks of treatment using Suboxone® (to study week 34) will ensue during which no CBT or CM therapies are provided. All participants enter a buprenorphine taper and return at study week 52 for long-term follow-up evaluations. Outcomes for the trial include illicit drug use (urine drug samples collected three times per week during the first 18 weeks), drug craving, retention (days in the protocol), psychiatric status (depression, mood), HIV risk behaviors, and treatment feasibility ratings. Results will be used to recommend strategies to optimize buprenorphine treatment outcomes and promote integration of pharmacotherapy and psychosocial/behavioral treatment strategies for physicians and for behavioral treatment facilities treating opioid-dependent patients.

Eligibility

Ages Eligible for Study:	15 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Participants must:

Be 15 years of age or older.
Meet DSM-IV-TR criteria for opioid dependence.
Be interested in receiving buprenorphine treatment for their opioid dependence.
Be in good general health or, in case of a medical/psychiatric condition needing ongoing treatment, be under the care of a physician who provides documented willingness to continue participant's medical management and coordinate care with the study physicians. *
Be agreeable to and capable of signing an informed consent.
Have means of reliable transportation over the study period.
If female and of child bearing potential, agree to use of one of the following methods of birth control or be surgically sterile:
1. oral contraceptives
2. patch
3. barrier (diaphragm or condom)
4. intrauterine contraceptive system
5. levonorgestrel implant
6. medroxyprogesterone acetate contraceptive injection
7. complete abstinence from sexual intercourse
8. hormonal vaginal contraceptive ring
Be agreeable to and capable of complying with study procedures.

Exclusion Criteria:

Participants must not:

Have a known sensitivity to buprenorphine or naloxone.
Be dependent on alcohol, benzodiazepines or other drugs of abuse that require immediate medical attention.
Have a medical condition that would, in the opinion of the study physician, make participation medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease).
Have a current pattern of benzodiazepine use, as assessed by the study physician, which would preclude safe participation in the study.
Be actively involved in another clinical trial.
Be acutely psychotic, severely depressed, and in need of inpatient treatment, or is an immediate suicide risk.
Be a nursing or pregnant female. Females who become pregnant during the course of the study will be withdrawn from the study and referred to an appropriate treatment venue; i.e. narcotic treatment program or specialty addiction clinic.
Be a female of childbearing potential who does not agree to use a medically acceptable method of birth control, e.g. oral contraceptives, barrier (diaphragm or condom) with or without spermicide, levonorgestrel implant, intra-uterine progesterone contraceptives system, medroxyprogesterone acetate contraceptive injection, or complete abstinence.
Have any pending legal action that could prohibit continued participation for the one-year period of study participation (such as that which could possibly result in incarceration).
Be expecting to leave the clinic's geographic area prior to study completion (within one year).
Have been previously randomized to a treatment condition in this study. -

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00591617

Locations

United States, California
UCLA Integrated Substance Abuse Programs Outpatient Clinical Research Center	Recruiting
Los Angeles, California, United States, 90025
Contact: Jackie Fahey, B.A. 310-267-5304 fahey@ucla.edu
Contact: Maureen P. Hillhouse, Ph.D. 310-267-5308 hillhous@ucla.edu

Sponsors and Collaborators

University of California, Los Angeles

Investigators

Principal Investigator:	Walter Ling, M.D.	UCLA Integrated Substance Abuse Programs
Study Director:	Maureen Hillhouse, Ph.D.	UCLA Integrated Substance Abuse Programs

More Information

No publications provided

Responsible Party:	UCLA ( Senior Contract and Grant Officer )
Study ID Numbers:	5R01DA020210
Study First Received:	December 28, 2007
Last Updated:	December 28, 2007
ClinicalTrials.gov Identifier:	NCT00591617 History of Changes
Health Authority:	United States: Institutional Review Board; United States: Data Safety and Monitoring Committee; United States: Research Advisory Panel of California

Keywords provided by University of California, Los Angeles:

Opioids
drug dependence
drug abuse
treatment

Study placed in the following topic categories:

Buprenorphine
Mental Disorders
Substance-Related Disorders

Disorders of Environmental Origin
Opioid-Related Disorders
Naloxone

Additional relevant MeSH terms:

Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders

ClinicalTrials.gov processed this record on July 02, 2009